Status:
SUSPENDED
Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries
Lead Sponsor:
Proneuron Biotechnologies
Collaborating Sponsors:
The Marcus Foundation
B.I.R.D. (Israel-U.S. Binational Industrial Research and Development)
Conditions:
Spinal Cord Injury
Eligibility:
All Genders
16-65 years
Phase:
PHASE2
Brief Summary
Autologous Incubated Macrophages (ProCord) is being developed as a therapy for acute, complete spinal cord injury (SCI). The therapy is intended to reverse the loss of motor and sensory function. Fol...
Eligibility Criteria
Inclusion
- Traumatic SCI during last 14 days
- Age 16 to 65 years
- Complete spinal cord injury (ASIA A)
- Neurological level : C5 to T11
- MRI showing lesion
Exclusion
- Women who are pregnant or breastfeeding
- Coma or other severe injury or disease
- Penetrating injury
- Ongoing mechanical ventilation
- Unsuitable based on MRI or other factor
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00073853
Start Date
September 1 2003
Last Update
August 28 2009
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Craig Hospital
Englewood, Colorado, United States, 80110
2
Shepherd Center
Atlanta, Georgia, United States, 30309
3
UMDNJ
Newark, New Jersey, United States, 07103
4
Kessler Medical Rehabilitation Research and Education Corporation
West Orange, New Jersey, United States, 07052